New hope for IBD patients: switching to guselkumab after ustekinumab fails
NCT ID NCT07245394
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Canadian study is testing whether switching to the drug guselkumab (Tremfya) can help people with inflammatory bowel disease (IBD) who didn't respond well enough to ustekinumab. Researchers will track symptoms, test results, and overall health in 200 participants over one year. The goal is to see if this switch can lead to better disease control without worsening endoscopic findings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (Tremfya)
What this could lead to
If successful, this could show that switching to guselkumab is a good option for people with IBD who didn't get enough relief from ustekinumab, offering better symptom control.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It's also relatively small (200 people) and only follows participants for one year, so long-term benefits or risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abp Research Services Corporation
RECRUITINGOakville, Ontario, L6L 5L7, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Barrie GI Associates
RECRUITINGBarrie, Ontario, L4M 7G1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Brampton Gastroenterology Research Group Inc
RECRUITINGBrampton, Ontario, L6S 0C1, Canada
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GNRR Digestive Clinics and Research Center Inc.
RECRUITINGBrampton, Ontario, L6S 0E2, Canada
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
LDDI Clinical Trials Inc. dba London Digestive Disease Institute
NOT_YET_RECRUITINGLondon, Ontario, N6K 1M6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MA MacMillan
RECRUITINGFredericton, New Brunswick, E3B 1J5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taunton Surgical Center
RECRUITINGOshawa, Ontario, L1J 0C7, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Toronto Immune and Digestive Health Institute
RECRUITINGToronto, Ontario, M6A3B4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
West Gta Research Inc.
RECRUITINGMississauga, Ontario, L5M 2S4, Canada
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••